Vena-caval apparatus and methods

US11839540B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11839540-B2
Application numberUS-202117487145-A
CountryUS
Kind codeB2
Filing dateSep 28, 2021
Priority dateJun 6, 2012
Publication dateDec 12, 2023
Grant dateDec 12, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Apparatus and methods are described including identifying a subject as suffering from a condition that causes the subject to have elevated central venous pressure. In response thereto, a device is placed inside the subject's vena cava, and the device is deployed inside the subject's vena cava, such that, in a passive manner, the device reduces blood pressure within the subject's renal veins relative to the subject's central venous pressure. Other applications are also described.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for use with renal veins and a vena cava of a subject, the method comprising: identifying the subject as suffering from a condition that causes the subject to have elevated central venous pressure; and in response thereto: placing a device inside the subject's vena cava; and deploying the device inside the subject's vena cava by deploying a first device in the subject's vena cava at a location upstream of junctions of the vena cava with one or more of the subject's renal veins and deploying a second device in the subject's vena cava at a location downstream of junctions of the vena cava with one or more of the subject's renal vein, such that, in a passive manner, the device reduces blood pressure within the subject's renal veins relative to the subject's central venous pressure. 2. The method according to claim 1 , wherein identifying the subject as suffering from a condition that causes the subject to have elevated central venous pressure comprises identifying the subject as suffering from at least one condition selected from the group consisting of: cardiac dysfunction, congestive heart failure, low renal blood flow, high renal vascular resistance, arterial hypertension, kidney dysfunction, and cardio-renal syndrome. 3. The method according to claim 1 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava, such that, in a passive manner, the device reduces pressure at a kidney of the subject by reducing the back flow of blood toward the kidney via the renal veins. 4. The method according to claim 1 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava, such that, in a passive manner, the device reduces renal venous pressure relative to central venous pressure, by protecting the renal vein from high central venous pressures. 5. The method according to claim 1 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava for a period of more than 12 hours and less than three months. 6. The method according to claim 1 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava such that the device passively protects a kidney of the subject from retrograde blood flow during periods of increased flow and pressure in the subject's vena cava that is generated by venous return from veins of the legs of the subject. 7. The method according to claim 1 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava such that the device passively reduces renal venous and interstitial pressure. 8. The method according to claim 1 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava such that the device passively causes improved renal salt and water excretion, by suppressing renin- angiotensin-aldosterone system (RAAS) activation, by suppressing arginine-vasopressin system activation. 9. The method according to claim 1 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava such that the device passively causes renal venous pressure to decrease such as to prevent or diminish a rise in renal parenchymal intracapsular pressure as a result of increased pressure and backflow from the inferior vena cava to the renal vein. 10. The method according to claim 1 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava such that the device passively attenuates activation of neural and endocrine control axes which generate the physiological effects that are responsible for heart failure syndrome. 11. The method according to claim 1 , wherein placing the first device inside the subject's vena cava comprises placing a nozzle inside the vena cava. 12. The method according to claim 1 , wherein placing the second device inside the subject's vena cava comprises placing a valve inside the vena cava. 13. The method according to claim 12 , wherein deploying the second device inside the subject's vena cava comprises deploying the valve inside the subject's vena cava, such that the valve passively reduces pressure at a kidney of the subject by reducing the back flow of blood toward the kidney via the subject's renal veins, by the valve closing in response to blood flowing back into the subject's renal veins. 14. The method according to claim 12 , wherein deploying the second device inside the subject's vena cava comprises deploying the valve inside the subject's vena cava, such that the valve passively protects the subject's renal veins from pressure increases resulting from high central venous pressure, by the valve closing in response to pressure within the vena cava downstream of the valve being greater than a threshold pressure. 15. The method according to claim 12 , wherein deploying the second device inside the subject's vena cava comprises deploying the valve inside the subject's vena cava at the location downstream of junctions of the vena cava with one or more of the subject's renal veins, the valve being configured to allow antegrade blood flow therethrough and to prevent retrograde blood flow therethrough. 16. The method according to claim 1 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava such that the device improves cardiac function of the subject. 17. The method according to claim 16 , wherein deploying the device inside the subject's vena cava comprises deploying the device inside the subject's vena cava such that the device reduces afterload. 18. A method for use with renal veins and a vena cava of a subject, the method comprising: identifying the subject as suffering from a condition that causes the subject to have elevated central venous pressure; and in response thereto: placing a device inside the subject's vena cava; and deploying the device inside the subject's vena cava, such that, in a passive manner, the device reduces blood pressure within the subject's renal veins relative to the subject's central venous pressure; wherein placing the device inside the subject's vena cava comprises placing a nozzle inside the vena cava; and wherein deploying the device inside the subject's vena cava further comprises deploying a valve inside the subject's vena cava at a location downstream of junctions of the vena cava with one or more of the subject's renal veins, the valve being configured to allow antegrade blood flow therethrough and to prevent retrograde blood flow therethrough.

Assignees

Inventors

Classifications

  • A61F2/2418Primary

    Scaffolds therefor, e.g. support stents · CPC title

  • Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07) · CPC title

  • Single tubular stent with a side portal passage · CPC title

  • Deployment by retracting a sheath · CPC title

  • made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11839540B2 cover?
Apparatus and methods are described including identifying a subject as suffering from a condition that causes the subject to have elevated central venous pressure. In response thereto, a device is placed inside the subject's vena cava, and the device is deployed inside the subject's vena cava, such that, in a passive manner, the device reduces blood pressure within the subject's renal veins rel…
Who is the assignee on this patent?
Magenta Medical Ltd
What technology area does this patent fall under?
Primary CPC classification A61F2/2418. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).